The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
|Articles|February 24, 2014
- Gastrointestinal Cancers (Issue 1)
- Volume 1
- Issue 1
The Identification of Molecular Subtypes of Gastric Cancer
Author(s)Pamela L. Kunz, MD
Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the need to identify molecular subtypes of gastric cancer.
Advertisement
Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the need to identify molecular subtypes of gastric cancer.
Learn more aboutthe treatment of gastric cancer > >
Articles in this issue
over 12 years ago
Ramucirumab Combo Increases Survival in Gastric Cancerover 12 years ago
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Dataover 12 years ago
New Standard of Neoadjuvant Care for Rectal Cancer Establishedover 12 years ago
Reducing the Risk of Relapse in Patients With Pancreatic Cancerover 12 years ago
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancerover 12 years ago
The Treatment of Advanced Colorectal CancerAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5